Unfortunately, the use of asparaginase‐containing regimens in AYA patients is complicated by hepatotoxicity in up to 60% of patients,3, 4, 5, 6, 7 with obesity conferring additional increased risk.3, 4, 5, 7, 8, 9, 10, 11. This evidence concerns the gene ASPG and obesity disorder.